Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

Video content above is prompted by the following:

• Briefly provide comments and perspectives on this patient case.
• Briefly comment on your approach to biomarker testing in patients with potentially resectable NSCLC?
  • What type of testing do you recommend? (e.g., single biomarker EGFR vs NGS)
  • How are you using biomarker testing pre- and post-surgery?
• How do you determine eligibility for surgical resection in patients with Stage III NSCLC at your practice and what factors influence patient selection for available surgical procedures? (e.g. mediastinoscopy, EBUS, lobectomy)